Regulatory Information
ABBVIE PTE. LTD.
ABBVIE PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
SOLUTION, STERILE
**2 DOSAGE AND ADMINISTRATION** The recommended dosage is one drop in the affected eye(s) once daily in the evening. **LUMIGAN** ® 0.01% (bimatoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect. Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours. **LUMIGAN** ® 0.01% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
OPHTHALMIC
Medical Information
**1 INDICATIONS AND USAGE** **LUMIGAN** ® 0.01% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
**4 CONTRAINDICATIONS** **LUMIGAN** ® 0.01% is contraindicated in patients with clinically significant hypersensitivity to bimatoprost or to any of the excipients.
S01EE03
bimatoprost
Manufacturer Information
ABBVIE PTE. LTD.
Allergan Pharmaceuticals Ireland
Active Ingredients
Documents
Package Inserts
LUMIGAN (BIMATOPROST OPHTHALMIC SOLUTION) 0.01% PI.pdf
Approved: December 1, 2021